“We are pleased that a first patient has been imaged in the CA-NINE trial, which supports potential label expansion for TLX250-CDx into recurrent, metastatic disease,” says David N. Cade. The first ...

Zaorsky discusses the patient safety misconceptions around radiotherapy for RCC, and considering patient-reported outcomes in future randomized controlled trials. New data presented at the American ...

Pastuszak discusses the evolving nature of understanding how testosterone therapy post-radiation for prostate cancer may beneficial or harmful to patients, and how to navigate the decision. Though ...

"When we looked at the same phenotypic data, but focusing on each immunochemistry protein markers, we had 10 patients with AR negative tumor with clearly worse prognosis, and synaptophysin-positive ...

Video content above is prompted by the following question: What are some unmet needs in prostate cancer care today, particularly regarding diagnosis, risk stratification and treatment? How can these ...

"At the University of Michigan, we've actually started to offer prostate MRI without contrast for patients on active surveillance, which has been a really exciting change," says Benjamin Pockros, MD, ...

At the 24-month time point, patients who received apalutamide had a 23% reduction in the risk of death compared with patients who initiated enzalutamide. Apalutamide (Erleada) was found to provide a ...

The 3-year biochemical progression-free survival was 61%, and the 3-year radiographic progression-free survival was 67%. Focal dose-escalated salvage high dose rate (HDR) brachytherapy demonstrated an ...

"The radiologist more than ever has to be part of the care team," says Phillip H. Kuo, MD, PhD, FACR. In this interview, Phillip H. Kuo, MD, PhD, FACR, discusses the key elements of a PSMA-PET report ...

Soumyajit Roy, MS, MBBS, explains how findings showing 5-year biochemical recurrence status may predict prostate cancer cure should alter the clinician-patient interaction. The implication of patient ...

Panelists discuss how non–muscle-invasive bladder cancer (NMIBC) presents with specific symptoms and diagnostic procedures, emphasize the significant economic burden on health care systems, and ...

"When determining which code you should use, you must consider your Medicare carrier’s published rules and commercial payer processing policies," write Jonathan Rubenstein, MD, and Mark Painter. The ...